BioSpace News Archive

The board of directors of Blue Cross Blue Shield of Massachusetts has elected Dorothy E. Puhy as chair of the board.

Pulmatrix, Inc. (NASDAQ: PULM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PUR1900 (“Pulmazole”), the Company’s inhaled itraconazole antifungal candidate being developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Sara Bonstein as Chief Financial Officer, effective January 31, 2020.

SutroVax, a biopharmaceutical company dedicated to developing best-in-class conjugate vaccines and novel complex antigen-based vaccines designed to prevent serious infectious diseases, today announced the appointment of Jim Wassil, MS, MBA as Chief Operating Officer

Arcadia Biosciences, Inc. (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, released the following letter today from the company’s President and Chief Executive Officer Matthew Plavan.

Lily Bioceuticals™ CEO Michael Kruel reports, “We’ve provided women over 40 with a much younger-looking face on which to apply make-up and it lasts an entire day and night.

Genetron Health, a China-based precision oncology company that provides full cycle cancer management solutions, announced it was selected to participate in 2019 China National Key Research and Development Project led by the China National Center for Biotechnology Development, to support research on development and evaluation of liquid biopsy technology for early screening of cancer.

Nihon Kohden, a U.S. market leader in precision medical products and services, today announced the commercial launch of its new NKV-550 Series Ventilator System, which offers a full suite of applications necessary in a critical care setting for patients of all ages – from neonate through adult.

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced the publication of new data in Pharmacology Research and Perspectives revealing further detail about the pharmacodynamics and utility of the company’s lead investigational medicine, COR388.

Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce that its wholly-owned subsidiary, Natural MedCo Ltd. (“Natural MedCo”), has entered into an exclusive letter of intent (the “LOI”) with ECS BioMed Inc. (“Dr. Kerklaan Therapeutics”) effective January 14, 2020.